Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-19
Target enrollment:
Participant gender:
Summary
The study is intended to assess the safety and efficacy of neoadjuvant Durvalumab in
combination with chemotherapy and Oleclumab or Monalizumab and adjuvant treatment in
participants with resectable, early-stage non-small cell lung cancer.